Abbott Biaxin XL
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryCompany's macrolide antibiotic clarithromycin gains approval Aug. 6 for new indication to treat mild to moderate community-acquired pneumonia caused by H. influenzae, H. parainfluenzae, M. catarrhalis, S. pneumoniae, C. pneumoniae and M. pneumoniae, in a seven-day treatment regimen
You may also be interested in...
Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further.
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.